



**Total Operational Revenue**  
**\$3,780,945**



**Net Assets** = \$47,400,671, mainly attributable to proceeds from the 2021 sale of the Priority Review Voucher (PRV) issued after the historic FDA approval of lonafarnib as a treatment for Progeria. PRF's 10-year average net assets prior to this historic payment = \$4.63 million.

**Total Expenses\***  
**\$5,259,932**



**\*Does not include in-kind services.** In 2024, PRF received approximately \$567,000 in pro bono legal, business and research consultant, and other professional services – thank you to everyone who donated their time and talents! If factored in, PRF's program ratio would exceed 83%.